Literature DB >> 16504183

Regulation of the transcription factor FOXM1c by Cyclin E/CDK2.

Juliane M Lüscher-Firzlaff1, Richard Lilischkis, Bernhard Lüscher.   

Abstract

The FOXM1 forkhead proteins, originally identified as M-phase phosphoproteins, are proliferation-associated transcriptional regulators involved in cell cycle progression, genetic stability and tumorigenesis. Here we demonstrate that Cyclin-dependent kinases regulate the transcriptional activity of FOXM1c. This is independent of an N-terminal negative regulatory domain and of the forkhead DNA binding domain. Instead we mapped the responsive sites in the transactivation domain. A combination of three phosphorylation sites mediates the Cyclin E and Cyclin A/CDK2 effects. Our findings provide evidence for a novel Cyclin E/CDK2 substrate that functions in cell cycle control.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504183     DOI: 10.1016/j.febslet.2006.02.021

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  27 in total

1.  Recovery from a DNA-damage-induced G2 arrest requires Cdk-dependent activation of FoxM1.

Authors:  Mónica Alvarez-Fernández; Vincentius A Halim; Lenno Krenning; Melinda Aprelia; Shabaz Mohammed; Albert J Heck; René H Medema
Journal:  EMBO Rep       Date:  2010-04-09       Impact factor: 8.807

2.  Regulation of a transcription factor network by Cdk1 coordinates late cell cycle gene expression.

Authors:  Benjamin D Landry; Claudine E Mapa; Heather E Arsenault; Kristin E Poti; Jennifer A Benanti
Journal:  EMBO J       Date:  2014-04-08       Impact factor: 11.598

3.  A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1.

Authors:  Yi-Ju Chen; Carmen Dominguez-Brauer; Zebin Wang; John M Asara; Robert H Costa; Angela L Tyner; Lester F Lau; Pradip Raychaudhuri
Journal:  J Biol Chem       Date:  2009-09-08       Impact factor: 5.157

Review 4.  Roles of FoxM1 in cell regulation and breast cancer targeting therapy.

Authors:  Xin Song; Samuel Selorm Fiati Kenston; Jinshun Zhao; Danting Yang; Yuanliang Gu
Journal:  Med Oncol       Date:  2017-02-08       Impact factor: 3.064

5.  FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.

Authors:  Richard E Francis; Stephen S Myatt; Janna Krol; Johan Hartman; Barrie Peck; Ursula B McGovern; Jun Wang; Stephanie K Guest; Aleksandra Filipovic; Ondrej Gojis; Carlo Palmieri; David Peston; Sami Shousha; Qunyan Yu; Piotr Sicinski; R Charles Coombes; Eric W-F Lam
Journal:  Int J Oncol       Date:  2009-07       Impact factor: 5.650

6.  Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain.

Authors:  Jamila Laoukili; Monica Alvarez; Lars A T Meijer; Marie Stahl; Shabaz Mohammed; Livio Kleij; Albert J R Heck; René H Medema
Journal:  Mol Cell Biol       Date:  2008-02-19       Impact factor: 4.272

7.  FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.

Authors:  J Millour; D Constantinidou; A V Stavropoulou; M S C Wilson; S S Myatt; J M-M Kwok; K Sivanandan; R C Coombes; R H Medema; J Hartman; A E Lykkesfeldt; E W-F Lam
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

8.  Cell cycle-dependent regulation of the forkhead transcription factor FOXK2 by CDK·cyclin complexes.

Authors:  Anett Marais; Zongling Ji; Emma S Child; Eberhard Krause; David J Mann; Andrew D Sharrocks
Journal:  J Biol Chem       Date:  2010-09-01       Impact factor: 5.157

Review 9.  Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases.

Authors:  Per Hydbring; Marcos Malumbres; Piotr Sicinski
Journal:  Nat Rev Mol Cell Biol       Date:  2016-04-01       Impact factor: 94.444

10.  Identification and functional analysis of a novel cyclin e/cdk2 substrate ankrd17.

Authors:  Min Deng; Fahui Li; Bryan A Ballif; Shan Li; Xi Chen; Lin Guo; Xin Ye
Journal:  J Biol Chem       Date:  2009-01-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.